Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1986 1
1987 2
1988 9
1989 7
1990 5
1991 2
1992 6
1993 5
1994 4
1995 5
1996 8
1997 8
1998 12
1999 2
2000 3
2002 3
2006 1
2007 2
2009 3
2010 5
2011 6
2012 1
2013 1
2014 4
2015 8
2016 3
2017 6
2018 3
2019 8
2020 8
2021 2
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic Innovations in Neuroscience: What's New on the Horizon?
Minichmayr IK, Ravenstijn P, van der Graaf PH, Vamvakas S. Minichmayr IK, et al. Among authors: vamvakas s. Clin Pharmacol Ther. 2022 Apr;111(4):715-717. doi: 10.1002/cpt.2547. Clin Pharmacol Ther. 2022. PMID: 35313013 No abstract available.
Glutathione-dependent toxicity.
Anders MW, Dekant W, Vamvakas S. Anders MW, et al. Among authors: vamvakas s. Xenobiotica. 1992 Sep-Oct;22(9-10):1135-45. doi: 10.3109/00498259209051867. Xenobiotica. 1992. PMID: 1441604 Review.
A mechanism of haloalkene-induced renal carcinogenesis.
Dekant W, Vamvakas S, Koob M, Köchling A, Kanhai W, Müller D, Henschler D. Dekant W, et al. Among authors: vamvakas s. Environ Health Perspect. 1990 Aug;88:107-10. doi: 10.1289/ehp.9088107. Environ Health Perspect. 1990. PMID: 2272303 Free PMC article. Review.
Glutathione-dependent bioactivation of xenobiotics.
Dekant W, Vamvakas S. Dekant W, et al. Among authors: vamvakas s. Xenobiotica. 1993 Aug;23(8):873-87. doi: 10.3109/00498259309059415. Xenobiotica. 1993. PMID: 8284943 Review.
Early market access of cancer drugs in the EU.
Martinalbo J, Bowen D, Camarero J, Chapelin M, Démolis P, Foggi P, Jonsson B, Llinares J, Moreau A, O'Connor D, Oliveira J, Vamvakas S, Pignatti F. Martinalbo J, et al. Among authors: vamvakas s. Ann Oncol. 2016 Jan;27(1):96-105. doi: 10.1093/annonc/mdv506. Epub 2015 Oct 20. Ann Oncol. 2016. PMID: 26487583 Free article. Review.
Marketing authorisation of orphan medicines in Europe from 2000 to 2013.
Hofer MP, Hedman H, Mavris M, Koenig F, Vetter T, Posch M, Vamvakas S, Regnstrom J, Aarum S. Hofer MP, et al. Among authors: vamvakas s. Drug Discov Today. 2018 Feb;23(2):424-433. doi: 10.1016/j.drudis.2017.10.012. Epub 2017 Oct 23. Drug Discov Today. 2018. PMID: 29074441 Free article. Review.
Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth.
Eichler HG, Pignatti F, Schwarzer-Daum B, Hidalgo-Simon A, Eichler I, Arlett P, Humphreys A, Vamvakas S, Brun N, Rasi G. Eichler HG, et al. Among authors: vamvakas s. Clin Pharmacol Ther. 2021 May;109(5):1212-1218. doi: 10.1002/cpt.2083. Epub 2020 Nov 12. Clin Pharmacol Ther. 2021. PMID: 33063841 Free PMC article. Review.
141 results